Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

MAGE-A1-derived peptide

Catalog No. TP2748Cas No. 160213-30-9

MAGE-A1-derived peptide is a short peptide sequence originating from the MAGE-A1 protein. Serving as a tumor-specific antigen, it can be recognized and activated by cytotoxic T lymphocytes (CTLs) to elicit an immune response against tumor cells expressing MAGE-A1. This immune response can result in the lysis and death of tumor cells. The peptide is utilized in research on tumor immunity.

MAGE-A1-derived peptide

MAGE-A1-derived peptide

Catalog No. TP2748Cas No. 160213-30-9
MAGE-A1-derived peptide is a short peptide sequence originating from the MAGE-A1 protein. Serving as a tumor-specific antigen, it can be recognized and activated by cytotoxic T lymphocytes (CTLs) to elicit an immune response against tumor cells expressing MAGE-A1. This immune response can result in the lysis and death of tumor cells. The peptide is utilized in research on tumor immunity.
Pack SizePriceAvailabilityQuantity
10 mgInquiryBackorder
50 mgInquiryBackorder
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
MAGE-A1-derived peptide is a short peptide sequence originating from the MAGE-A1 protein. Serving as a tumor-specific antigen, it can be recognized and activated by cytotoxic T lymphocytes (CTLs) to elicit an immune response against tumor cells expressing MAGE-A1. This immune response can result in the lysis and death of tumor cells. The peptide is utilized in research on tumor immunity.
Chemical Properties
Molecular Weight1090.36
FormulaC53H91N11O13
Cas No.160213-30-9
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy MAGE-A1-derived peptide | purchase MAGE-A1-derived peptide | MAGE-A1-derived peptide cost | order MAGE-A1-derived peptide | MAGE-A1-derived peptide chemical structure | MAGE-A1-derived peptide formula | MAGE-A1-derived peptide molecular weight